New RA drug KT502 enters first human safety trial
NCT ID NCT07564154
First seen May 05, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called KT502 in 27 adults with moderate to severe rheumatoid arthritis who haven't responded well to other treatments. The goal is to check if the drug is safe, what side effects it may cause, and how the body processes it. Participants will receive the drug as a shot under the skin, with doses gradually increased to find the best level.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kali Therapeutics Trial Site
Bayswater, Victoria, Australia
-
Kali Therapeutics Trial Site
Auckland, NZ, New Zealand
Conditions
Explore the condition pages connected to this study.